2 results
Approved WMOWill not start
1 Confirm comparable results in reduction and consolidation of the fracture fragments using the LFN vs the UFN2 Identifying a significant difference in the soft tissue damage between the LFN and the UFN
Approved WMOPending
The primary objectives of this trial are:• Part 1 (dose escalation): To evaluate the safety of BYON4228 alone and in combinationwith rituximab to determine the maximum tolerated dose (MTD), or optimal biological dose(OBD) if the MTD is not reached,…